Scientific deep-dive
Lifestyle Plus the Drug
Across 98,261 people, taking a GLP-1 and keeping six to eight healthy habits meant 43% fewer cardiovascular events than three or fewer habits and no drug. The two figures people will compare cannot be compared.
The tiresome argument about whether people should “just eat better instead” has an answer now, from 98,261 people followed across 632,543 person-years. Doing both beat doing either. People taking a GLP-1 and keeping six to eight healthy habits had 43% fewer major cardiovascular events than people with three or fewer habits and no drug.[1]
What was measured
| Comparison | Hazard ratio |
|---|---|
| All eight low-risk lifestyle habits vs one or fewer | 0.40 (95% CI 0.30–0.54) |
| GLP-1 users vs non-users | 0.84 (95% CI 0.76–0.92) |
| GLP-1 plus six to eight habits vs three or fewer habits and no GLP-1 | 0.57 (95% CI 0.46–0.71) |
The authors’ conclusion is that combining lifestyle change with pharmacotherapy produced a greater reduction than either approach alone.[1]
The comparison you cannot make from this table
It is tempting to set 0.40 against 0.84 and conclude lifestyle is roughly four times more powerful than the drug. That comparison is not available, and it is the misreading this study will be used for.
The rows are different contrasts. One compares the extremes of an eight-point gradient; the other compares taking a drug against not taking it.
“Eight habits versus one or fewer” contrasts the healthiest people in the dataset against the least healthy across a wide range of behaviors. “GLP-1 user versus non-user” is a single yes-or-no. Those produce numbers that cannot be ranked against each other, any more than you could compare the effect of “the top versus bottom of a scale” with “on versus off a switch”.
There is a second problem specific to lifestyle findings in observational data. Adhering to eight healthy habits is not a randomly distributed trait — it correlates with income, housing, working hours, disability, and every other advantage that independently predicts cardiovascular outcomes. Adjustment helps and does not remove it.
What the finding does support
- The two are not alternatives. This is the useful part, and it is the opposite of how the choice is usually framed publicly.
- Taking the drug does not make lifestyle irrelevant. The combined group did better than drug users generally.
- The drug is not a substitute for the habits, and the habits are not a reason to refuse the drug. Both directions of that sentence are supported here.
- It is consistent with the randomized picture. In a four-arm trial we covered in exercise plus a GLP-1, the drug alone did nothing for physical fitness while exercise did, and the combination did most.
Frequently Asked Questions
References
- 1.Nguyen XT, Li Y, Czernichow S, et al. Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes The Lancet Diabetes & Endocrinology. 2026. PMID: 41763234.
Compare the sellers
Related research
How Far You Can Walk
Peripheral artery disease stops people walking, and almost nothing improves it. A trial of 792 people measured actual walking distance, and the spread matters as much as the median.
6 min read
Exercise Plus a GLP-1: What Each One Actually Changes
In a four-arm randomized trial, the drug alone produced no improvement in physical fitness. Exercise alone did. Both together did most, and the strength result needs reading carefully.
6 min read
Muscle Loss: Drug Versus Dieting
Across 20 trials in 15,782 people, the share of weight lost as lean mass was the same on incretin drugs as on dieting (p=0.42). Adding resistance training cut it from about a quarter to 17.5%.
6 min read
Stopping as a Clinical Transition
A review argues discontinuation is a high-risk clinical transition, and reports an association with later heart disease that another review says barely exists as data. Both are describing the same thin literature.
6 min read
The Cardiovascular Cost of Stopping
A review argues that weight and blood sugar fluctuation are themselves cardiovascular risk factors, and that these drugs do not stabilize arteries the way statins do. It also says few data exist on hard outcomes after stopping.
5 min read
A Benefit Nobody Observed
A cardiology journal reports GLP-1 therapy could cut ten-year cardiovascular risk by 22% in people who have never had heart disease. Nobody in the study took the drug.
6 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Sesame Care
Oral orforglipron alongside the injectables
Pricing Compare
Get started →Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
Pricing Compare
Get started →Found
Tirzepatide at $169/month, 37% below the typical price
Pricing Compare
Get started →